Co-Authors
This is a "connection" page, showing publications co-authored by Bassam Hallis and Sue Charlton.
Connection Strength
0.643
-
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc. 2021 06; 16(6):3114-3140.
Score: 0.235
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
Score: 0.060
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
Score: 0.059
-
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat Commun. 2021 02 24; 12(1):1260.
Score: 0.058
-
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 04 29; 184(9):2348-2361.e6.
Score: 0.058
-
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 04 15; 184(8):2201-2211.e7.
Score: 0.058
-
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat Commun. 2021 01 04; 12(1):81.
Score: 0.058
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
Score: 0.057